Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: A randomized trial

Diabetes, Obesity and Metabolism

Volumn 12, Issue 10, 2010, Pages 916-922

  Strojek, K ^a   Shi, C ^b   Carey, M A ^c   Jacober, S J ^d  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b I3 Statprobe/UHG   (United States)

^c I3 Statprobe/UHG   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

HbA1c; Hypoglycaemia; Insulin lispro protamine suspension; Non inferiority; Type 2 diabetes; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMAPEN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN LISPRO PROTAMINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENETICILLIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEVERE HYPOGLYCEMIA; SUSPENSION; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

EID: 77956138372     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01257.x     Document Type: Article

References (10)

1. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203..
2. Raccah D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab 2008, 10((Suppl. 2)):76-82..
3. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev 2007, 23:257-264..
4. Hompesch M, Ocheltree SM, Wondmagegnehu ET. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009, 25:2679-2687..
5. Esposito K, Ciotola M, Maiorino MI. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008, 149:531-539..
6. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naïve patients with type 2 diabetes. Diabet Med 2010, 27:181-188.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553..
8. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 1994, The Criteria Committee of the New York Heart Association., Boston, MA, Little, Brown & Co.
9. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086..
10. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008, 51:408-416..